Breath Volatile Organic Compounds Patterns of Lung Transplant Patients With Chronic Lung Allograft Dysfunction
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02836938 |
Recruitment Status :
Completed
First Posted : July 19, 2016
Last Update Posted : February 14, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Chronic Lung Allograft Dysfunction (CLAD) | Other: Collection of exhaled breath volatile organic compounds |
Study Type : | Observational |
Actual Enrollment : | 75 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Study Start Date : | June 2016 |
Actual Primary Completion Date : | December 2016 |
Actual Study Completion Date : | December 2016 |
Group/Cohort | Intervention/treatment |
---|---|
Severe
Severe chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 3
|
Other: Collection of exhaled breath volatile organic compounds |
Mild
Mild chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 1-2
|
Other: Collection of exhaled breath volatile organic compounds |
Control
Bronchiolitis obliterans syndrome (BOS), stage 0
|
Other: Collection of exhaled breath volatile organic compounds |
- Concentration of exhaled breath volatile organic compounds [ Time Frame: one sample will be collected between 6 month and 20 years after lung transplantation ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Outpatient bilateral lung transplant recipients including combined transplants
Exclusion Criteria:
- Active Smoking Oxygen therapy Infection with multi or pan-resistant bacteria

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02836938
Germany | |
Hannover Medical School | |
Hannover, Germany, 30625 |
Responsible Party: | Prof. Dr. Jens Hohlfeld, Prof. Dr., Fraunhofer-Institute of Toxicology and Experimental Medicine |
ClinicalTrials.gov Identifier: | NCT02836938 |
Other Study ID Numbers: |
TXVOC |
First Posted: | July 19, 2016 Key Record Dates |
Last Update Posted: | February 14, 2017 |
Last Verified: | February 2017 |